Ask AI
ProCE Banner Activity

Tardive Dyskinesia: Using Pharmacologic Principles to Create an Individualized Treatment Plan

Slideset

Tardive dyskinesia (TD) presents important challenges in psychopharmacologic management, particularly for patients requiring long-term antipsychotic treatment. These downloadable slides from Psychopharmacology Update 2026 review TD risk factors, screening and assessment strategies, and evidence-based treatment approaches. Explore the pharmacology of VMAT2 inhibitors with practical considerations for dosing, drug interactions, and individualized treatment selection.

Released: November 18, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Neurocrine Biosciences.

Neurocrine Biosciences

Target Audience

This educational activity is intended for psychiatrists, geriatricians, neurologists, nurse practitioners, physician associates, general and family practice physicians, long-term care pharmacists, psychologists, social workers, and other healthcare professionals who treat patients or advise HCP care teams regarding their patients with tardive dyskinesia who may benefit from this education. Target audiences for specific satellite symposia are adjusted as appropriate for each conference.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze the pharmacologic mechanisms, metabolic pathways, and treatment emergent risks associated with antipsychotic medications that contribute to the development of tardive dyskinesia

  • Compare the pharmacokinetic and pharmacodynamic profiles of available VMAT2 inhibitors

  • Demonstrate how the characteristics of available VMAT2 inhibitors inform dosing, titration, and clinical decision making in TD management

  • Integrate evidence based pharmacologic strategies into individualized treatment plans for TD, considering comorbid psychiatric conditions, concomitant medications, and long term therapeutic goals in diverse and complex scenarios

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.